NCT04711915Active, not recruitingPhase 1
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Source: ClinicalTrials.gov · Last updated 3 Aug 2025
Brief summary (registry, in English)
The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 12 Jan 2021
- Start date
- 17 Mar 2021
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Yale University
- Diseases
- Depression
- NCT number
- NCT04711915
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 17 Mar 2021 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Healthy controls inclusion criteria:
- Medically healthy
- Psychiatrically healthy
- Healthy controls exclusion criteria:
- Unstable medical conditions
- Psychiatric illness
- Depression inclusion criteria:
- Medically healthy
- Diagnosis of major depressive disorder
- Depression exclusion criteria:
- -Unstable medical conditions
Age in the registry: 21 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, Coordinator of this site? Confirm its status | West Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.